Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma

Original Article: Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma

More From BioPortfolio on "Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications